Advice

following an abbreviated submission:

tacrolimus (Envarsus®) prolonged release-tablets are accepted for use within NHS Scotland.

Indication under review: Prophylaxis of transplant rejection in adult kidney or liver allograft recipients and treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
                                                                                                                                                                                                  Tacrolimus (Envarsus®) is suitable for use by patients for whom tacrolimus is an appropriate choice of immunosuppressive therapy. It has increased bioavailability compared with other tacrolimus preparations.  Tacrolimus (Envarsus®) has demonstrated non-inferiority to a tacrolimus immediate-release capsule and has a similar cost per equivalent dose.
 

Download detailed advice50KB (PDF)

Download

Medicine details

Medicine name:
tacrolimus (Envarsus)
SMC ID:
1041/15
Indication:
Prophylaxis of transplant rejection in adult kidney or liver allograft recipients and treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
Pharmaceutical company
Chiesi Limited
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated
Status
Accepted
Date advice published
13 April 2015